Ye Tingmin, Tang Chunping, Yang Dandan, Zhang Qing, Liao Yufen, Dai Jie, Tang Hong, Ke Changqiang, Peng Ying, Ye Yang, Li Weiwei, Zheng Jiang
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Guizhou Medical University, Guiyang, 550004, PR China.
State Key Laboratory of Drug Research, and Natural Products Chemistry Department, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR China.
Chem Biol Interact. 2025 Oct 8;419:111630. doi: 10.1016/j.cbi.2025.111630. Epub 2025 Jul 1.
Bavachin (BVC), a flavonoid, is found in Psoraleae fructus (PF) which has been reported to induce various adverse effects, particularly hepatotoxicity, such as increases of serum alanine transaminase (ALT) and aspartate transaminase (AST) in mice given BVC. However, the mechanisms underlying its hepatotoxicity remain unclear. During the incubation of mouse microsomes with BVC in the presence of glutathione (GSH) or N-acetylcysteine (NAC), one oxidative metabolite (M1), one GSH conjugate (M2), and one NAC conjugate (M3) were observed. M1 was successfully synthesized by selective oxidation of BVC. Similar microsomal incubations of synthetic M1 offered M2 and M3. Following oral administration of BVC, the presence of biliary M2 and urinary M3 was observed in mice given BVC. CYP3A identified as the major enzyme was involved in the metabolic activation of BVC. The metabolic activation of BVC involved hydroxylation of BVC and sequential oxidation of the hydroxylation product to the corresponding o-quinone derivative. BVC treatment resulted in significant cytotoxicity in cultured mouse primary hepatocytes, and pretreatment with 1-aminobenzotriazole and ketoconazole decreased the susceptibility of hepatocytes to the cytotoxicity of BVC. Oral administration of PF extract resulted in a quick decline in hepatic GSH, along with the detection of GSH conjugate M2, in mice. BVC, a principal component of PF, was also found to deplete hepatic GSH in mice over a brief period. This evidence suggests that metabolic activation of BVC leads to depletion of GSH in vivo and that BVC contributes to the depletion of hepatic GSH caused by PF extract.
补骨脂素(BVC)是一种黄酮类化合物,存在于补骨脂果实(PF)中,据报道,PF会引发多种不良反应,尤其是肝毒性,比如给小鼠服用BVC后,其血清丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)会升高。然而,其肝毒性的潜在机制仍不清楚。在谷胱甘肽(GSH)或N-乙酰半胱氨酸(NAC)存在的情况下,将小鼠微粒体与BVC一起孵育时,观察到一种氧化代谢物(M1)、一种GSH缀合物(M2)和一种NAC缀合物(M3)。通过BVC的选择性氧化成功合成了M1。对合成的M1进行类似的微粒体孵育可得到M2和M3。口服BVC后,在服用BVC的小鼠中观察到胆汁中有M2,尿液中有M3。已确定主要酶CYP3A参与了BVC的代谢活化。BVC的代谢活化包括BVC的羟基化以及羟基化产物依次氧化为相应的邻醌衍生物。BVC处理导致培养的小鼠原代肝细胞出现明显的细胞毒性,用1-氨基苯并三唑和酮康唑预处理可降低肝细胞对BVC细胞毒性的敏感性。给小鼠口服PF提取物后,肝脏GSH迅速下降,同时检测到GSH缀合物M2。PF的主要成分BVC在短时间内也会使小鼠肝脏GSH耗竭。这一证据表明,BVC的代谢活化会导致体内GSH耗竭,并且BVC会导致PF提取物引起的肝脏GSH耗竭。